Trends in Molecular Medicine, Год журнала: 2024, Номер unknown
Опубликована: Дек. 1, 2024
Язык: Английский
Trends in Molecular Medicine, Год журнала: 2024, Номер unknown
Опубликована: Дек. 1, 2024
Язык: Английский
bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown
Опубликована: Янв. 14, 2025
Abstract To overcome the paucity of known tumor-specific surface antigens in pediatric high-grade glioma (pHGG), we contrasted splicing patterns pHGGs and normal brain samples. Among alternative events affecting extracellular protein domains, most pervasive alteration was skipping ≤30 nucleotide-long microexons. Several these skipped microexons mapped to L1-IgCAM family members, such as NRCAM . Bulk single-nuclei short- long-read RNA-seq revealed uniform 5 19 virtually every pHGG sample. Importantly, Δex5Δex19 (but not full-length) proteoform essential for cell migration invasion vitro tumor growth vivo. We developed a monoclonal antibody selective demonstrated that “painting” cells with this enables killing by T armed an FcRI-based universal immune receptor. Thus, pHGG-specific possibly other proteoforms are promising highly targets adoptive immunotherapies. Statement significance Existing chimeric antigen receptors (CAR)-armed often shared CNS tumors tissues, creating potential on-target/off-tumor toxicities. Here demonstrate glial origin, adhesion molecules have alternatively spliced proteoforms, which could be targeted therapeutic antibodies.
Язык: Английский
Процитировано
0Trends in Pharmacological Sciences, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0Nature, Год журнала: 2025, Номер unknown
Опубликована: Фев. 19, 2025
Язык: Английский
Процитировано
0bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown
Опубликована: Март 5, 2025
Abstract CD19-CAR-T-cells emerge as a major therapeutic option for relapsed/refractory B-cell-derived malignancies, however approximately half of patients eventually relapse. To identify resistance-driving factors, we repeatedly exposed B-cell lymphoma/B-cell acute lymphoblastic leukemia to 4-1BB/CD28-based in vitro . Generated models revealed costimulatory domain-dependent differences CD19 loss. While CD19-4-1BB-CAR-T-cells induced combination epitope/total protein loss, CD19-CD28-CAR-T-cells did not drive antigen-escape. Consistent with observations relapsing after CD19-4-1BB-CAR-T-cells, identified frameshift/missense mutations affecting residues critical FMC63 epitope recognition. Mathematical simulations that between CD19-4-1BB- and activity against low-antigen-expressing tumor contribute heterogeneous responses. By integrating silico data, propose biological scenario where fail eliminate low-antigen cells, fostering CAR-resistance. These findings offer mechanistic insight into the observed clinical axi-cel (CD28-based) tisa-cel (4-1BB-based)-treated lymphoma advance our understanding on CAR-T resistance. Furthermore, underscore need specific detection deliver information antigen levels accessible CD19-CAR-T-cells. Visual abstract
Язык: Английский
Процитировано
0NAR Cancer, Год журнала: 2025, Номер 7(2)
Опубликована: Апрель 2, 2025
Abstract SRSF2 (serine/arginine-rich splicing factor 2) is a critical regulator of pre-messenger RNA splicing, which also plays noncanonical functions in transcription initiation and elongation. Although elevated levels are associated with advanced stages lung adenocarcinoma (LUAD), the mechanisms connecting to tumor progression remain unknown. We show that overexpression increases global replicative stress LUAD cells, correlates production DNA damage, notably double-strand breaks (DSBs), likely resulting from conflicts between replication. Moreover, regulates repair pathways by promoting homologous recombination inhibiting nonhomologous end joining. Mechanistically, interacts enhances MRE11 (meiotic 11) recruitment chromatin, while downregulating 53BP1 messenger protein levels. Both events contributing SRSF2-mediated process rerouting. Lastly, we expression commonly predicts poor outcome patients. Altogether, our results identify mechanism promotes cancer through fine control both DSB repair. Finally, knockdown impairs late ionizing radiation-induced DSBs, suggesting more function recombination.
Язык: Английский
Процитировано
0Trends in Molecular Medicine, Год журнала: 2024, Номер unknown
Опубликована: Дек. 1, 2024
Язык: Английский
Процитировано
2